Article

Genetic Predisposition to Alzheimer’s Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region

Iacopo Ciampa 1, Grégory Operto 2,3,4, Carles Falcon 2,3,5,*, Carolina Minguillon 2,3,4, Manuel Castro de Moura 6, David Piñeyro 6,7,*, Manel Esteller 6,7,8,9, Jose Luis Molinuevo 2,3,4,10,11,*, Roderic Guigo 10,11,*, Arcadi Navarro 2,8,11,12, Juan Domingo Gispert 2,3,5,*, Natalia Vilor-Tejedor 2,10,11,13,*, and for the ALFA Study ‡

Citation: Ciampa, I.; Operto, G.; Falcon, C.; Minguillon, C.; Castro de Moura, M.; Piñeyro, D.; Esteller, M.; Molinuevo, J.L.; Guigo, R.; Navarro, A.; et al. Genetic Predisposition to Alzheimer’s Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region. Genes 2021, 12, 825. https://doi.org/10.3390/genes12060825

Abstract: This study investigated whether genetic factors involved in Alzheimer’s disease (AD) are associated with enlargement of Perivascular Spaces (ePVS) in the brain. A total of 680 participants with T2-weighted MRI scans and genetic information were acquired from the ALFA study. ePVS in the basal ganglia (BG) and the centrum semiovale (CS) were assessed based on a validated visual rating scale. We used univariate and multivariate logistic regression models to investigate associations between ePVS in BG and CS with BIN1-rs744373, as well as APOE genotypes. We found a significant association of the BIN1-rs744373 polymorphism in the CS subscale (p value = 0.019; OR = 2.564), suggesting that G allele carriers have an increased risk of ePVS in comparison with A allele carriers. In stratified analysis by APOE-ε4 status (carriers vs. non-carriers), these results remained significant only for ε4 carriers (p value = 0.011; OR = 1.429). To our knowledge, the present study is the first suggesting that genetic predisposition for AD is associated with ePVS in CS. These findings provide evidence that underlying biological processes affecting AD may influence CS-ePVS.

Keywords: APOE-ε4; BIN1-rs744373; enlargement of perivascular spaces; neurogenetics; virchow robin spaces
1. Introduction

Perivascular spaces (PVS) are pial-lined and interstitial fluid-filled spaces in the brain surrounding the cerebral vessel walls that can be detectable in vivo by Magnetic Resonance Imaging (MRI) [1].

Enlargement of perivascular spaces (ePVS) in the brain is common but is generally overlooked and is of uncertain pathophysiology. Accumulated evidence suggests that ePVS correlates with aging [2], cognition [3], inflammatory processes [4], and cerebrovascular diseases [5], as well as with neurodegenerative pathologies [6,7]. Specifically, some previous studies have reported an association between ePVS and pathologic features of Alzheimer's disease (AD) [8,9]. Other studies have reported that the frequency and severity of MRI-visible PVS are greater in AD than in cognitively unimpaired individuals [10–12]. However, the relationship between ePVS and AD is still poorly understood.

Identifying whether the genetic basis of AD influences ePVS in cognitively unimpaired individuals may provide additional insights into the neurobiological abnormalities that underlie AD.

The Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport. It also has an important role in Aβ metabolism, one of the pathological hallmarks of AD. It is well established that, even in asymptomatic AD stages, the APOE-ε4 allele triggers Aβ accumulation not only in the brain parenchyma but also in the perivascular region, the latter leading to cerebral amyloid angiopathy (CAA), in which blood vessel function is disrupted [13]. In addition, amyloid-independent effects of APOE have been described on tau neurofibrillary degeneration, microglia and astrocyte responses, and blood-brain barrier disruption [14]. In particular, it has been recently shown that APOE-ε4 can also increase blood-brain barrier permeability in the hippocampus and medial temporal lobe, contributing to cognitive decline independently of AD pathology [15]. However, controversial results have been found about its influence in ePVS [16,17].

Along with APOE, the Bridging integrator 1 (BIN1) gene has been identified as an influential risk locus for AD [18,19]. BIN1 is involved in the retrieval of synaptic vesicles, and ubiquitous isoforms of BIN1 participate in inflammatory processes. Specifically, the BIN1 rs744373 polymorphism has been reported as a modulator of tau clearance [20,21], which could provide a possible neural mechanism underlying the association between BIN1 polymorphism and risk for AD. This genetic variant presents two possible alleles, A (major allele) and G (minor allele), the latter being associated with AD and thus considered the risk allele [22,23]. Although BIN1 has been linked with lipid metabolism [24] and neuroinflammatory pathways [25], the exact pathogenic mechanisms of BIN1 in the AD pathophysiological process remain to be determined, and no study to date has examined its involvement in ePVS.

In this study, we aimed to investigate whether APOE and BIN1 are associated with ePVS burden (Figure 1).
2. Material and Methods

2.1. Participants

Participants were drawn from the ALFA study (Alzheimer and Families) carried out in the Barcelonaβeta Brain Research Center [26]. The ALFA study is composed of 2743 cognitively unimpaired participants, mostly adult children of patients with AD, and aged between 45 and 75 years. A subset of 680 participants with available information on BIN1-rs744373 SNP and APOE genotypes, as well as having an MRI examination, were included in this study. The study sample is a large cohort of cognitively unimpaired individuals after an exhaustive neuropsychological and clinical screening procedure; therefore, results should not be confounded by comorbidities of dementia, being the individuals of the study at a low mean of cardiovascular risk.

2.2. Standard Protocol Approvals, Registrations, and Patient Consents

The study was conducted in accordance with the directives of the Spanish Law 14/2007, of 3rd of July, on Biomedical Research (Ley 14/2007 de Investigación Biomédica). The ALFA study protocol was approved by the Independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov, accessed on 25 May 2021 (Identifier: NCT01835717). All participants accepted the study procedures by signing the study’s informed consent form that had also been approved by the same IRB.

2.3. Genotyping

Genome-wide genotyping was performed using the Illumina Infinium NeuroChip backbone [27], based on a genome-wide genotyping array (Infinium HumanCore-24 v1.0 and Infinium HumanCore-24 v1.2). PLINK was used for the quality control (QC) of genetic data [28]. We applied the following sample QC thresholds: sample missingness rates > 2%, and heterozygosity less than 4 standard deviations. Additionally, we exclude individuals showing sex discordances and higher genetic relatedness (IBD > 0.185). Further details can be found in Reference [29]. The final genetic data set of the present study consisted of 680 participants of European ethnic origin with available information regarding BIN1-rs744373 polymorphism and APOE genotypes. Departures from Hardy-Weinberg equilibrium and
allele frequencies were also inspected. The APOE allelic variants were obtained from allelic combinations of the rs429358 and rs7412 polymorphism [30]. According to the genotypes of these polymorphisms, subjects were classified depending on APOE-ε4 status (non-carriers vs. carriers), the number of ε4 alleles (non-carriers, one ε4 allele, or two ε4 alleles), and APOE allelic variants (ε3ε3, ε2ε3, ε3ε4, and ε4ε4). Subjects were also classified depending on BIN1-rs744373 G allele status (non-carriers vs. carriers).

2.4. Image Acquisition and Rating of ePVS

Scans were obtained with a 3T scanner (Philips Ingenia CX, Eindhoven, Netherlands). The MRI protocol was identical for all participants and included high-resolution 3D T2-weighted structural images: Turbo Spin Echo, 256 × 256, 1 × 1 × 1 mm³ matrix, TR/TE: 2500/264 ms, flip angle = 90°. In addition, a 3D T1-weighted TFE sequence was acquired (voxel size 0.75 × 0.75 × 0.75 mm³, TR/TE: 9.90/4.6 ms, flip angle = 8°), as well as a 3D T2-FLAIR sequence (voxel size 1 × 1 × 1 mm³, TR/TE: 5000/312 ms). Scans were visually assessed for quality and incidental findings by a trained neuroradiologist.

ePVS were quantified independently in basal ganglia (BG) and centrum semiovale (CS) regions by a radiologist based on high-resolution T2-weighted images. The radiologist was blinded to other variables of the study. A visual rating scale used in previous publications [31–34] was used to code ePVS. Specifically, ePVS were assessed in the slice and hemisphere with the highest number, and rated as 0 (no PVS), 1 (mild; 1–10 PVS), 2 (moderate; 11–20 PVS), 3 (frequent; 21–40 PVS), or 4 (severe; >40 PVS).

Participants were dichotomized according to the severity of the ePVS rating of the BG and CS (degrees 0–2 were categorized as non-severe or 0; degrees 3–4 were categorized as severe or 1). The intra-rater agreement rate of the PVS scale was evaluated using a Kappa-Cohen agreement test on a random sample of 20% of the subjects in the dataset (κ = 0.77, p = 6.02 × 10⁻⁸ for BG subscale; and κ = 0.76, p = 8.2 × 10⁻¹⁰ for CS subscale).

2.5. Statistical Analysis

Differences in demographic variables were tested using the χ² test and F test for gender, age, years of education, number of APOE-ε4 alleles, and BIN1-rs744373 genotype.

The association between APOE genotypes and BIN1 rs744373 polymorphism with the ePVS subscales and with the total scale were assessed by computing odds ratios (OR) using univariate and multivariate logistic regression models corrected by age, sex, and years of education. Dominant genetic models were assumed for BIN1 rs744373. Briefly, in dominant models, homozygous of the major allele (i.e., AA genotype) were compared to heterozygous and homozygous of the minor allele (i.e., AG, GG genotypes).

For APOE genotype, we adjusted three models. In the first model, we compared ε4 carriers vs. non-carriers (APOE status). In the second model, we compared individuals depending on the number of ε4 alleles. Finally, in the third model, we compared ε3ε3 individuals (reference category) vs. ε2ε3, ε3ε4, and ε4ε4. APOE-ε2ε4 individuals were excluded in all analyses. Moreover, we additionally stratified the analysis of BIN1 rs744373 polymorphism by APOE-ε4 status, and we explored interaction effects between BIN1 rs744373 and APOE-ε4 status. To assess the association between demographic variables and ePVS, we additionally computed ORs using logistic regression models.

Statistical significance was set at False Discovery Rate (FDR) corrected p value < 0.05 (Benjamini-Hochberg procedure). All statistical analyses and data visualization were carried out using R version 3.4.4.

3. Results

3.1. Sample Descriptive

Tables 1 and 2 show the characteristics of the sample. We divided the participants according to the severity of their ePVS rating in the BG and CS. We obtained two different categories for each region, with 550 non-severe and 130 severe BG ratings, and 227 non-severe and 453 severe CS ratings.
Table 1. Characteristics of the study’s sample according to basal ganglia rating. Mean and SD are shown for continuous variables.

|                          | Non-Severe BG Rating (n = 550) | Severe BG Rating (n = 130) | Total (n = 680) | p (χ², F) |
|--------------------------|---------------------------------|-----------------------------|-----------------|-----------|
| Age (m ± SD; years)      | 58.99 (±6.5)                    | 64.02 (±5.81)               | 59.95 (±6.67)   | 0.120     |
| Sex (female), n (%)      | 374 (68%)                       | 86 (66%)                    | 460 (67%)       | 0.763     |
| Education (m ± SD; years)| 13.58 (±3.42)                   | 13 (±3.41)                  | 13.47 (±3.42)   | 0.987     |
| APOE-ε4 carriers, n (%)  | 221 (40%)                       | 59 (45%)                    | 280 (41%)       | 0.324     |
| Number of APOE-ε4 alleles, n (%) | 0:329 (60%); 1:192 (35%); 2:29 (5%); | 0:71 (55%); 1:47 (36%); 2:12 (9%); | 0:400 (59%); 1:239 (35%); 2:41 (6%); | 0.195     |
| APOE-ε4 isoforms, n (%)  | 33:297 (54%); 34:180 (33%); 44:29 (5%); | 33:60 (46%); 34:46 (35%); 44:12 (9%); | 33:357 (52%); 34:226 (33%); 44:41 (6%); | 0.068     |
| BIN1-rs744373 G allele carriers n (%) | 280 (51%); 65 (50%); | 345 (51%)       | 345 (51%)       | 0.929     |

Legend: n, sample size; m, mean; SD, standard deviation; p, p value; BG, basal ganglia.

Table 2. Characteristics of the study’s sample according to Centrum Semiovale rating. Mean and SD are shown for continuous variables.

|                          | Non-Severe CS Rating (n = 227) | Severe CS Rating (n = 453) | Total (n = 680) | p (χ², F) |
|--------------------------|---------------------------------|-----------------------------|-----------------|-----------|
| Age (m ± SD; years)      | 58.06 (±5.75)                   | 60.9 (±6.9)                 | 59.95 (±6.67)   | 0.002     |
| Sex (female), n (%)      | 155 (68%)                       | 305 (67%)                   | 460 (67%)       | 0.87      |
| Education (m ± SD; years)| 13.21 (±3.47)                   | 13.6 (±3.39)                | 13.47 (±3.42)   | 0.663     |
| APOE-ε4 carriers, n (%)  | 87 (38%)                        | 193 (43%)                   | 280 (41%)       | 0.323     |
| Number of APOE-ε4 alleles, n (%) | 0:140 (62%); 1:77 (34%); 2:10 (4%); | 0:260 (57%); 1:162 (36%); 2:31 (7%); | 0:400 (59%); 1:239 (35%); 2:41 (6%); | 0.348     |
| APOE genotypes, n (%)    | 33:126 (55%); 34:73 (32%); 44:10 (4%); | 33:231 (51%); 34:153 (34%); 44:31 (7%); | 33:357 (52%); 34:226 (33%); 44:41 (6%); | 0.776     |
| BIN1-rs744373 G allele carriers n (%) | 130 (57%); 215 (47%); | 345 (51%)       | 345 (51%)       | 0.019     |

Legend: n, sample size; m, mean; SD, standard deviation; p, p value; CS, Centrum Semiovale.

3.2. APOE and ePVS

The APOE-ε4 allele was present in 280 individuals (41% of the sample). Of them, 239 (35% of the sample) were APOE-ε4 heterozygous, and 41 (6% of the sample) APOE-ε4 homozygous. In both subscales, the presence of APOE-ε4 alleles was generally, more frequent in severe cases, while the APOE-ε3ε3 genotype was, in general, more frequent in non-severe cases (Tables 1 and 2).

We did not observe a significant association between APOE and ePVS. Specifically, significant differences between being an ε4 carrier, and the ePVS subscales in both regions (BG p value = 0.379, CS p value = 0.445) were not found. In addition, we did not observe significant associations between the number of ε4 alleles (0, 1, or 2) and the subscales (BG p value = 0.546 and 0.088, CS p value = 0.475 and 0.174). Finally, significant associations between APOE genotype and the subscales were not found either (Table 3).
Table 3. Associations between enlargement of Perivascular Spaces in basal ganglia and centrum semiovale. rs744373 polymorphisms and APOE genotype. Models were adjusted by age, sex, and education. ▲ False-discovery rate-corrected p-values.

|                      | Basal Ganglia |                  |                  | Centrum Semiovale |                  |                  |
|----------------------|---------------|------------------|------------------|-------------------|------------------|------------------|
|                      | OR (IC 95%)   | p-Value ▲       |                  | OR (IC 95%)       | p-Value ▲       |                  |
| **Age (years)**      | 1.121 [1.087;1.155] | <0.001          |                  | 1.071 [1.043;1.099] | <0.001          |                  |
| **Sex**              |               |                  |                  |                   |                  |                  |
| Male                 | Ref.          | Ref.             |                  | Ref.              | Ref.            |                  |
| Female               | 1.17 [0.721;1.626] | 0.437           | 1.044 [0.743;1.474] | 0.743            |                  |                  |
| **APOE genotypes**   |               |                  |                  |                   |                  |                  |
| ε3ε3                 | Ref.          | Ref.             |                  | Ref.              | Ref.            |                  |
| ε2ε3                 | 1.256 [0.481;2.879] | 0.620           | 1.039 [0.506;2.239] | 0.918            |                  |                  |
| ε3ε4                 | 1.265 [0.822;1.937] | 0.282           | 1.142 [0.803;1.631] | 0.460            |                  |                  |
| ε4ε4                 | 2.057 [0.956;4.193] | 0.064           | 1.672 [0.816;3.721] | 0.165            |                  |                  |
| **APOE-ε4 non-carriers** |           |                  |                  |                   |                  |                  |
| Male                 |               | Ref.             |                  | Ref.              | Ref.            |                  |
| Female               | 1.19 [0.839;1.818] | 0.379           | 1.194 [0.862;1.658] | 0.445            |                  |                  |
| **APOE-ε4 genotypes**|               |                  |                  |                   |                  |                  |
| 0 alleles            | Ref.          | Ref.             |                  | Ref.              | Ref.            |                  |
| 1 allele             | 1.135 [0.750;1.706] | 0.546           | 1.132 [0.806;1.596] | 0.475            |                  |                  |
| 2 alleles            | 1.927 [0.902;3.893] | 0.088           | 1.651 [0.809;3.663] | 0.174            |                  |                  |
| **BIN1-rs744373 (dominant model)** |       |                  |                  |                   |                  |                  |
| AA genotype          | Ref.          | Ref.             |                  | Ref.              | Ref.            |                  |
| AG + GG genotype     | 1.037 [0.707;1.522] | 0.848           | 1.481 [1.075;2.049] | 0.022            |                  |                  |

Legend: Ref., Reference category; OR, Odds Ratio. Dominant models tested: BIN1-rs744373 GG group vs. BIN1-rs744373 GA and AA group.

3.3. BIN1-rs744373 and ePVS

The BIN1 rs744373-G allele was present in 345 individuals (51% of the sample). In the CS subscale, this allele was more frequent in the severe category (57%) than in the non-severe one (47%). We observed significant association of the BIN1-rs744373 SNP in the CS subscale (p value = 0.022; OR = 1.481), suggesting that G-allele carriers have an increased risk of PVS enlargement in comparison with A-allele carriers. These results remained significant in stratified analysis by APOE-ε4 status, albeit only in ε4 allele carriers (p value = 0.013; OR = 2.009) (Figure 2).

No significant associations were found in the BG region (Table 3), neither interactive significant associations between BIN1-rs744373 and APOE genotypes.

3.4. Age-Dependent Effects

We observed significant effects of age in both subscales (p value < 0.001), suggesting that older people are more likely to have ePVS in these regions irrespective of genetic predisposition to AD (Table 3). These results were independent of genetic associations (Figure 2). Years of education were significantly associated with CS-ePVS only in APOE-ε4 non-carriers (OR = 1.01, p value = 0.045). No significant associations were found for sex.
Figure 2. Associations (Odds Ratios) between enlargement of Perivascular Spaces in basal ganglia and centrum semiovale regions and BIN1-rs744373 polymorphism, stratified by APOE genotypes. Models were adjusted by age, sex, and years of education. *p*-values were corrected using the false discovery rate (FDR) method. *** p-value < 5 × 10^{-5}; ** p-value < 5 × 10^{-3}; * p-value < 5 × 10^{-2}.

4. Discussion

In this study, we investigated the association between ePVS and relevant genetic factors related to AD (i.e., the APOE genotype and BIN1-rs744373 polymorphism). We found significant associations between BIN1-rs744373 in the CS region, suggesting that G-allele carriers, which have OR = 1.7 of developing AD, have an increased risk of ePVS in comparison with A-allele carriers. These results were significant only in APOE-ε4 carriers, suggesting that only those with a higher genetic predisposition to AD are associated with ePVS in CS. In addition, we did not find significant associations between APOE genotype or status and ePVS, which is in line with previous studies [11,35] and suggests that a multiple genetic predisposition to AD may affect ePVS.

To our knowledge, there were no previous studies that investigated the association of BIN1 and ePVS. This gene is known for encoding a set of proteins generated by alternative RNA splicing with functions in membrane and actin dynamics, cell polarity, and stress signaling and has been identified as a relevant significant risk locus for late-onset AD [18,19]. Other studies have found that BIN1 is involved in the neural degeneration of hippocampal, middle temporal, posterior cingulate, and precuneus regions, influencing the metabolism of glucose in the temporal lobe throughout the AD process [36]. Furthermore, other studies have found that the BIN1 locus is strongly associated with poorer memory performance...
without observing associations with brain MRI markers. These results led to the hypothesis that \textit{BIN1} may exert its influence on the development of AD via mechanisms not visualized by structural MRIs, like amyloid-deposition or tau-pathology [37,38]. Indeed, other researchers found evidence that \textit{BIN1} could contribute to the progression of AD-related tau pathology by altering tau clearance and promoting the release of tau-enriched extracellular vesicles by microglia via exosomes secretion [18] and by increasing aggregate internalization by endocytosis [37].

However, the characteristics of our study do not allow us to disentangle the molecular mechanisms associated with the observed effects of \textit{APOE} and \textit{BIN1} on ePVS. Unfortunately, biomarkers of AD pathology were not available in this sample to unravel whether the observed effects are mediated by amyloid and/or tau pathology. Given the main roles of \textit{APOE} and \textit{BIN1}, it could be speculated that, in \textit{APOE-ε4} carriers, who are expected to harbor higher levels of amyloid pathology, the presence of the \textit{BIN1}-rs744373 polymorphism can present with even further higher levels of amyloid and/or tau and lead to a disruption of the interstitial fluid dynamics in the brain. An alternative putative mechanism may involve the endosome-lysosome pathway resulting in an earlier and/or more severe AD-related neurodegeneration, which has also been associated with ePVS. However, the level of neurodegeneration in our participants is expected to be rather small, if any, given that they are cognitively unimpaired. Finally, since \textit{APOE, BIN1}, and ePVS have all been reported to play an important role in the immune response of the brain, it could also be hypothesized that neuroinflammatory processes might be contributing to the effects observed in our work. Further studies, including biomarkers of core AD pathology and neuroinflammatory mechanisms, which are currently being collected in this sample, may help address these questions.

Another important aspect of our results is the dependence on ePVS topography. For instance, we found significant results in the CS region, but not in the BG. Interestingly, some previous studies reported that CS-ePVS appears to be associated with a clinical diagnosis of AD [12,39] (i.e., cerebral Aβ pathologies), whereas ePVS in the BG appears to be associated with subcortical vascular cognitive impairment [40,41]. However, literature on this is scarce, and some of these results were obtained from the analysis of heterogeneous populations (i.e., showing considerable differences correlating with the presence of cardiovascular risk factors). These differences make it difficult to extrapolate from the results, and this issue requires further research in homogenous populations.

A number of limitations in this study must be considered. Particularly challenging was the evaluation of MRIs with very small ePVS that can be seen as faint, indistinct, high signal structures, since those can cause a change from one category to another if considered. In addition, we should take into account that ePVS are a crude simplification of the complex anatomical brain patterns, and are not uniform across the lifespan. Moreover, the results should be interpreted considering the unavailability of a replication sample. Finally, the study sample belongs to a cognitively unimpaired population; thus, the identified associations cannot be interpreted to exert a causal relationship with the clinical presentation of AD.

However, the characteristics of the studied cohort, as well as the higher prevalence of the G allele of \textit{BIN1}-rs744373 polymorphism and the \textit{APOE-ε4} allele, allow us achieving an unprecedented statistical power in comparison with studies with similar number of individuals that are genetically closer to the general population [42].

In conclusion, our findings suggest that genetic risk factors for AD are associated with ePVS in CS. These results may provide evidence that the biological pathways affecting AD may influence ePVS in CS.

**Author Contributions:** Major role in the quantification of ePVS; analyze the data, interpret the data and draft the manuscript were conducted by I.C. Acquisition of neuroimaging data was performed by G.O. and C.F. Acquisition of genetic data by C.M., M.C.d.M., D.P., M.E. Major role in the acquisition of ALFA study data was conducted by J.L.M. Writing and editing by A.N. and R.G. Conceptualization
of the study, interpretation of the results, writing and supervise the project were done by J.D.G. and N.V.-T. All authors have read and agreed to the published version of the manuscript.

**Funding:** The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SL002/16/00201). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya. JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation—Spanish State Research Agency.

**Institutional Review Board Statement:** The ALFA study was approved by the Independent Ethics Committee “Parc de Salut Mar”, Barcelona, and registered at Clinicaltrials.gov (Identifier: NCT01835717).

**Informed Consent Statement:** All participating subjects signed the study’s informed consent form that had also been approved by the Independent Ethics Committee “Parc de Salut Mar”, Barcelona.

**Data Availability Statement:** To protect participants’ privacy, individual level data cannot be made publicly available. Researchers who wish to use data from the ALFA study must obtain approval from the ALFA study Management Team (research@barcelonabeta.org).

**Acknowledgments:** This publication is part of the ALFA (ALZheimer and FAmilies) study. The authors would like to express their most sincere gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Müge Akinci, Annabella Beteta, Raffaele Cacciaglia, Alba Cañas, Irene Cumplido, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Carles Falcon, Karine Fauria, Sherazede Fuentes, Oriol Grau-Rivera, Laura Hernandez, Gema Huesa, Jordi Huget, Iva Knezevic, Eider M. Arenaza-Urquijo, Paula Marme, Tania Menchón, Marta Milà-Alomà, Gréory Operto, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernández, Aleix Sala-Vila, Gemma Salvadó, Gonzalo Sánchez-Benavides, Anna Soteras, Laura Stankeviciute, Marc Suárez-Calvet, and Marc Vilanova.

**Conflicts of Interest:** J.L.M. is currently a full time employee of Lundbeck and priorly has served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. The remaining authors declare that they have no conflict of interest.

**References**

1. Wardlaw, J.M.; Benveniste, H.; Nedergaard, M.; Zlokovic, B.V.; Mestre, H.; Lee, H.; Doublal, F.N.; Brown, R.; Ramirez, J.; Maclntosh, B.J.; et al. Perivascular spaces in the brain: Anatomy, physiology and pathology. *Nat. Rev. Neurol.* 2020, 16, 137–153. [CrossRef] [PubMed]
2. Zong, X.; Lian, C.; Jimenez, J.; Yamashita, K.; Shen, D.; Lin, W. Morphology of perivascular spaces and enclosed blood vessels in young to middle-aged healthy adults at 7T: Dependences on age, brain region, and breathing gas. *NeuroImage* 2020, 218, 116978. [CrossRef] [PubMed]
3. Kelsey, R. Perivascular spaces are associated with cognition. *Nat. Rev. Neurol.* 2019, 15, 246–247. [CrossRef] [PubMed]
4. Wuerfel, J.; Haertle, M.; Waiczies, H.; Tysiak, E.; Bechmann, I.; Wernecke, K.D.; Zipp, F.; Paul, F. Perivascular spaces—MRI marker of inflammatory activity in the brain? *Brain* 2008, 131, 2332–2340. [CrossRef]
5. Brown, R.; Benveniste, H.; E Black, S.; Charpak, S.; Dichgans, M.; Joutel, A.; Nedergaard, M.; Smith, K.J.; Zlokovic, B.V.; Wardlaw, J.M. Understanding the role of the perivascular space in cerebral small vessel disease. *Cardiovasc. Res.* 2018, 114, 1462–1473. [CrossRef]
6. Chan, S.T.; Mercaldo, N.D.; Ravina, B.; Hersch, S.M.; Rosas, H.D. Association of dilated perivascular spaces and disease severity in patients with Huntington’s disease. *Neurology* 2021, 96, e890-e894. [CrossRef]
7. Ding, J.; Sigurðsson, S.; Jönsson, P.V.; Eiriksdottir, G.; Charidimou, A.; Lopez, O.L.; A Van Buchem, M.; Guðnason, V.; Launer, L.J. Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia. *JAMA Neurol.* 2017, 74, 1105–1112. [CrossRef]
8. Weller, R.O.; Boche, D.; Nicoll, J.A.R. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. *Acta Neuropathol.* **2009**, *118*, 87–102. [CrossRef]

9. Boespflug, E.L.; Simon, M.J.; Leonard, E.; Grafe, M.; Wolfgar, R.; Silbert, L.C.; Kaye, J.A.; Iliff, J.J. Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer’s Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer’s Disease. *J. Alzheimer's Dis.* **2018**, *66*, 1587–1597. [CrossRef] [PubMed]

10. Smeijer, D.; Ikram, M.K.; Hilal, S. Enlarged Perivascular Spaces and Dementia: A Systematic Review. *J. Alzheimer's Dis.* **2019**, *72*, 247–256. [CrossRef]

11. Shams, S.; Martola, J.; Charidimou, A.; Larvie, M.; Granberg, T.; Shams, M.; Kristofferson-Wiberg, M.; Wahlin, L.-O. Topography and determinants of magnetic resonance imaging (MRI)-visible perivascular spaces in a large memory clinic cohort. *J. Am. Heart Assoc.* **2017**, *6*, e006279. [CrossRef] [PubMed]

12. Banerjee, G.; Kim, H.J.; Fox, Z.; Jäger, H.R.; Wilson, D.; Charidimou, A.; Na, H.K.; Na, D.L.; Seo, S.W.; Werring, D.J. MRI-visible perivascular space location is associated with Alzheimer’s disease independently of amyloid burden. *Brain* **2017**, *140*, 1107–1116. [CrossRef]

13. Liu, C.-C.; Kanekiyo, T.; Xu, H.; Bu, G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nat. Rev. Neurol.* **2013**, *9*, 106–118. [CrossRef] [PubMed]

14. Serrano-Pozo, A.; Das, S.; Hyman, B.T. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. *Lancet Neurol.* **2021**, *20*, 68–80. [CrossRef]

15. Montagne, A.; Nation, D.A.; Sagare, A.P.; Barisano, G.; Sweeney, M.D.; Chakhchouk, A.; Pachcano, M.; Joe, E.; Nelson, A.R.; D’Orazio, L.M.; et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. *Nature* **2020**, *581*, 71–76. [CrossRef]

16. Kim, J.; Basak, J.M.; Holtzman, D.M. The Role of Apolipoprotein E in Alzheimer’s Disease. *Neuron* **2009**, *63*, 287–303. [CrossRef] [PubMed]

17. Luo, X.; Jaerken, Y.; Yu, X.; Huang, P.; Qiu, T.; Jia, Y.; Li, K.; Xu, X.; Shen, Z.; Guan, X.; et al. Associations between APOE genotype and cerebral small-vessel disease: A longitudinal study. *Oncotarget* **2017**, *8*, 44477–44489. [CrossRef]

18. Bertram, L.; McQueen, M.B.; Mullin, K.; Blacker, D.; E Tanzi, R. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. *Nat. Genet.* **2007**, *39*, 17–23. [CrossRef] [PubMed]

19. Tan, M.-S.; Yu, J.-T.; Tan, L. Bridging integrator 1 (BIN1): Form, function, and Alzheimer’s disease. *Trends Mol. Med.* **2013**, *19*, 594–603. [CrossRef] [PubMed]

20. Franzmeier, N.; Rubinski, A.; Neitzel, J.; Ewers, M.; The Alzheimer’s Disease Neuroimaging Initiative (ADNI). The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. *Nat. Commun.* **2019**, *10*, 1–12. [CrossRef]

21. Crotti, A.; Sait, H.R.; McAvoy, K.M.; Estrada, K.; Wilson, D.; Charidimou, A.; Na, H.K.; Na, D.L.; Seo, S.W.; Werring, D.J. MRI-visible perivascular space location is associated with Alzheimer’s disease independently of amyloid burden. *Brain* **2017**, *140*, 1107–1116. [CrossRef]

22. Lambert, J.C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; DeStafano, A.L.; Bis, J.C.; Beecham, G.W.; Grenier-Boley, B.; et al. Meta-Analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat. Genet.* **2013**, *45*, 1452–1458. [CrossRef]

23. Jansen, I.E.; Savage, J.E.; Watanabe, K.; Bryois, J.; Williams, D.M.; Steinberg, S.; Sealock, J.; Karlsson, I.K.; Hägg, S.; Athanasiu, L.; et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. *Nat. Genet.* **2019**, *51*, 404–413. [CrossRef] [PubMed]

24. Jones, L.; Harold, D.; Williams, J. Genetic evidence for the involvement of lipid metabolism in Alzheimer’s disease. *Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids* **2010**, *1801*, 754–761. [CrossRef] [PubMed]

25. Villegas-Llerena, C.; Phillips, A.; Garcia-Reitboeck, P.; Hardy, J.; Pocock, J.M. Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. *Curr. Opin. Neurobiol.* **2016**, *36*, 74–81. [CrossRef]

26. Molinuevo, J.L.; Gramunt, N.; Gispert, J.D.; Fauria, K.; Esteller, M.; Minguillon, C.; Serrano-Pozo, A.; Grau-Rivera, O.; et al. Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ε4 in middle-age cognitively unimpaired individuals from the ALFA study. *Brain Struct. Funct.* **2020**, *225*, 2331–2345. [CrossRef]

27. Villegas-Llerena, C.; Phillips, A.; Garcia-Reitboeck, P.; Hardy, J.; Pocock, J.M. Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. *Curr. Opin. Neurobiol.* **2016**, *36*, 74–81. [CrossRef]

28. Blauwendraad, J.; Faghi, F.; Pihlstrom, L.; Geiger, J.T.; Elbaz, A.; Lesage, S.; Corvol, J.-C.; May, P.; Nicolas, A.; Abramzon, Y.; et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. *Neurobiol. Aging* **2017**, *57*, 247.e9–247.e13. [CrossRef]

29. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am. J. Hum. Genet.* **2007**, *81*, 559–575. [CrossRef]

30. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am. J. Hum. Genet.* **2007**, *81*, 559–575. [CrossRef]

31. Vilor-Tejedor, N.; for the ALFA Study; Operto, G.; Evans, T.E.; Falcon, C.; Crous-Bou, M.; Cacciaglia, R.; Milà-Alomà, M.; Grau-Rivera, O.; et al. Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ε4 in middle-age cognitively unimpaired individuals from the ALFA study. *Brain Struct. Funct.* **2020**, *225*, 2331–2345. [CrossRef] [PubMed]

32. Van Den Broecke, A.; Adam, K.; Devan, W.J.; Anderson, C.D.; Rosand, J.; Falcone, G.J. Accuracy of imputation to infer unobserved APOE epsilon alleles in genome-wide genotyping data. *Eur. J. Hum. Genet.* **2014**, *22*, 1239–1242. [CrossRef] [PubMed]

33. A Heier, L.; Bauer, C.J.; Schwartz, L.; Zimmerman, R.D.; Morgello, S.; Deck, M.D. Large Virchow-Robin spaces: MR-clinical correlation. *Am. J. Neuroradiol.* **1989**, *10*, 929–936.
32. MacLullich, A.M.J.; Wardlaw, J.M.; Ferguson, K.J.; Starr, J.M.; Seckl, J.R.; Deary, I.J. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. *J. Neurol. Neurosurg. Psychiatry* 2004, 75, 1519–1523. [CrossRef] [PubMed]

33. Doubal, F.N.; MacLullich, A.M.; Ferguson, K.J.; Dennis, M.S.; Wardlaw, J.M. Enlarged Perivascular Spaces on MRI Are a Feature of Cerebral Small Vessel Disease. *Stroke* 2010, 41, 450–454. [CrossRef] [PubMed]

34. Potter, G.M.; Chappell, F.M.; Morris, Z.; Wardlaw, J.M. Cerebral Perivascular Spaces Visible on Magnetic Resonance Imaging: Development of a Qualitative Rating Scale and its Observer Reliability. *Cerebrovasc. Dis.* 2015, 39, 224–231. [CrossRef] [PubMed]

35. Zhu, Y.C.; Tzourio, C.; Soumaré, A.; Mazoyer, B.; Dufouil, C.; Chabriat, H. Severity of dilated virchow-robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: A population-based study. *Stroke* 2010, 41, 2483–2490. [CrossRef] [PubMed]

36. Wang, H.-F.; Yu, J.-T.; Tan, L. Bridging integrator 1 (BIN1) genotypes Induce Alzheimer’s disease—Related Brain atrophy, abnormal glucose and Aβ metabolisms in ADNI cohort (P2.159). *Neurology* 2015, 84 (Suppl. S14).

37. Calafate, S.; Flavin, W.; Verstreken, P.; Moechars, D. Loss of Bin1 Promotes the Propagation of Tau Pathology. *Cell Rep.* 2016, 17, 931–940. [CrossRef]

38. Cook, C.; Kang, S.S.; Carломagno, Y.; Lin, W.-L.; Yue, M.; Kurti, A.; Shinohara, M.; Jansen-West, K.; A Perkerson, E.; Castanedes-Casey, M.; et al. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. *Hum. Mol. Genet.* 2015, 24, 6198–6212. [CrossRef]

39. Charidimou, A.; Gang, Q.; Werring, D.J. Sporadic cerebral amyloid angiopathy revisited: Recent insights into pathophysiology and clinical spectrum. *J. Neurol. Neurosurg. Psychiatry* 2011, 83, 124–137. [CrossRef]

40. Martinez-Ramirez, S.; Pontes-Neto, O.M.; Dumas, A.P.; Auriel, E.; Halpin, A.; Quimby, M.; Gurol, M.E.; Greenberg, S.M.; Viswanathan, A. Topography of dilated perivascular spaces in subjects from a memory clinic cohort. *Neurology* 2013, 80, 1551–1556. [CrossRef]

41. Patankar, T.F.; Mitra, D.; Varma, A.; Snowden, J.; Neary, D.; Jackson, A. Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: Study in elderly patients with dementia. *Am. J. Neuroradiol.* 2005, 26, 1512–1520. [PubMed]

42. Cacciaglia, R.; Molinuevo, J.L.; Falco, C.; Brugulat-Serrat, A.; Sanchez-Benavides, G.; Gramunt, N.; Esteller, M.; Moràn, S.; Minguillón, C.; Fauria, K.; et al. Effects of APOE-e4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer’s disease. *Alzheimer's Dement.* 2018, 14, 902–912. [CrossRef]